Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).

The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

COMy 2026 | Practical management of bispecific antibody therapy in multiple myeloma

Meral Beksaç, MD, Istinye University Ankara Liv Hospital, Ankara, Turkey, discusses practical management of bispecific antibody therapy in multiple myeloma, including strategies for monitoring and treating cytokine release syndrome (CRS) and reducing infection risk. She highlights the growing use of preemptive tocilizumab, IVIG support, and outpatient administration as experience with these therapies expands. This interview took place at the 12th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

This question reminds me of our experience when we experienced immunotherapy such as the bispecific for the first time like in four years ago. We were so afraid to manage CRS, how to recognize and how to treat, but through the years we have come to notice that with bispecific, especially those which we use for myeloma, CRS is not a big issue. You can treat them easily, and tocilizumab is a very helpful agent...

This question reminds me of our experience when we experienced immunotherapy such as the bispecific for the first time like in four years ago. We were so afraid to manage CRS, how to recognize and how to treat, but through the years we have come to notice that with bispecific, especially those which we use for myeloma, CRS is not a big issue. You can treat them easily, and tocilizumab is a very helpful agent. And nowadays, there is more data coming in to use tocilizumab preemptively to prevent hospitalization and to allow outpatient administration. So for community doctors, of course, this requires experience, but like everything else, when we start a new drug, the first steps are you need to be more cautious, more careful, but in time you learn. So it’s the learning curve that matters the most. And I’m sure community doctors will be able to handle this. And if they have the capacity to hospitalize patients, that’s okay. And the other thing which they have to be more alerted about is the rate of infections. And the use of intravenous immunoglobulin frequently, like with three to four weeks of intervals and taking care of the IgG level and also accounting for the clonal IgG and not to miss the real hypogammaglobulinemia. In that fashion, the rate of infections will be less, and use of routine antibiotics, especially the quinolone type of antibiotics, is becoming more widespread. So these are the major two issues that I think will be very helpful for those centers.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.